TapImmune Begins Phase 2 Trial of T-cell Therapy for Platinum-sensitive Ovarian Cancer Patients

TapImmune Begins Phase 2 Trial of T-cell Therapy for Platinum-sensitive Ovarian Cancer Patients
TapImmune has initiated a Phase 2 clinical trial to evaluate the T-cell therapy TPIV 200 in platinum-sensitive ovarian cancer patients. Following regulatory and Investigational Review Board (IRB) approval, the first three clinical sites were allowed to begin enrolling patients. The multicenter, randomized Phase 2 clinical trial (NCT02978222) will evaluate the activity of TPIV 200, a T-cell therapy

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *